Elevating Drug Development with NAMs: Meeting the FDA’s Call for Change
Regulatory agencies and industry innovators are accelerating the push to utilize scientifically validated New Approach Methodologies (NAMs), which aim to provide more human-relevant preclinical drug safety and efficacy data while eliminating unnecessary animal testing. In April 2025, the FDA unveiled the Roadmap to Reducing Animal Testing in Preclinical Safety Studies, mentioning potential incentives for regulatory review, and the NIH announced that they will no longer issue Notices of Funding Opportunities exclusively supporting animal models.
BioIVT will host a panel of industry experts for a series of presentations and discussions around the development, validation, and utilization of NAMs for a variety of ADME-Tox applications.
Javelin Presentation: Elucidating Complex Drug-Drug Interaction Mechanisms of Chronic Rifampicin Exposure in Liver Tissue Chip